KALA BIO (KALA) Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. More details

KALA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 34% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($57M)

KALA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

KALA BIO, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for KALA BIO
Historical stock prices
Current Share Price	US$2.93
52 Week High	US$1,030.00
52 Week Low	US$2.85
Beta	-2.24
1 Month Change	-70.52%
3 Month Change	-85.58%
1 Year Change	-98.40%
3 Year Change	-99.65%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Oct 20

Kala Pharmaceuticals to execute reverse stock split

Kala Pharmaceuticals (NASDAQ:KALA) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s (KALA) issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. The split will reduce the number of shares of common stock outstanding from 73,208,140 shares to ~1,464,163 shares, subject to adjustment for the rounding up of fractional shares. The stock will will begin trading on a split-adjusted basis when the market opens on Friday, October 21, 2022. KALA shares are down over 2% premarket

Seeking Alpha • Aug 10

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.36 (+36.8% Y/Y) and the consensus Revenue Estimate is $2.02M (-33.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

Shareholder Returns

	KALA	US Biotechs	US Market
7D	-26.1%	-1.6%	-0.9%
1Y	-98.4%	34.4%	24.4%

Return vs Industry: KALA underperformed the US Biotechs industry which returned 40.3% over the past year.

Return vs Market: KALA underperformed the US Market which returned 26.7% over the past year.

Price Volatility

Is KALA's price volatile compared to industry and market?
KALA volatility
KALA Average Weekly Movement	18.5%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KALA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: KALA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2009	6	Avi Minkowitz	kalarx.com

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company products include legacy KPI-012 research, focuses on scientific and data analysis; MSC-S and PCED research, focuses on agentic workflows on trial data; and Researgency.ai, focuses on enterprise AI product development. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.

KALA BIO, Inc. Fundamentals Summary

How do KALA BIO's earnings and revenue compare to its market cap?
KALA fundamental statistics
Market cap	US$57.44m
Earnings (TTM)	-US$26.98m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.0x

P/E Ratio

Is KALA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KALA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$26.98m
Earnings	-US$26.98m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-1.45
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did KALA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/15 06:51
End of Day Share Price	2026/05/15 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KALA BIO, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tazeen Ahmad	BofA Global Research
Biren Amin	Jefferies LLC
Christopher Neyor	J.P. Morgan

KALA BIO (KALA) Stock Overview

Rewards

Risk Analysis

KALA BIO, Inc. Competitors

Adicet Bio

Genelux

XBiotech

Inovio Pharmaceuticals

Price History & Performance

Recent News & Updates

KALA BIO, Inc. announced delayed annual 10-K filing

Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent

Kala Bio Announces Launch Of First Commercial AI Product

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

Kala Bio, Inc. Receives Notice of Nasdaq Minimum Bid Price Non-Compliance

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Recent updates

KALA BIO, Inc. announced delayed annual 10-K filing

Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent

Kala Bio Announces Launch Of First Commercial AI Product

KALA BIO, Inc. Announces Resignation of David Lazar as Director, Effective February 16, 2026

Kala Bio, Inc. Receives Notice of Nasdaq Minimum Bid Price Non-Compliance

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

KALA BIO, Inc., Annual General Meeting, Jan 30, 2026

KALA BIO, Inc. has filed a Follow-on Equity Offering in the amount of $9.99909 million.

KALA BIO, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective December 1, 2025

KALA BIO, Inc. announced delayed 10-Q filing

KALA BIO, Inc. Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

KALA BIO, Inc. announced that it expects to receive $0.375 million in funding

KALA BIO, Inc. Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA BIO Appoints Todd Bazemore as Chief Executive Officer

New major risk - Revenue and earnings growth

New major risk - Share price stability

New major risk - Financial position

Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect

Chairman notifies of intention to sell stock

New major risk - Revenue and earnings growth

New major risk - Share price stability

New minor risk - Share price stability

KALA BIO, Inc. Announces Chief Executive Officer Changes

KALA BIO, Inc. announced that it has received $10.749667 million in funding

KALA BIO, Inc. announced that it expects to receive $10.749667 million in funding

New major risk - Share price stability

Price target decreased by 15% to US$16.50

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Consensus revenue estimates fall by 27%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Price target decreased to US$5.25

Shareholder Returns

Price Volatility

About the Company

KALA BIO, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake